TABLE IV.
Clinical characteristics of subjects
| Mild | n | Moderate | n | Severe | n | P value | |
|---|---|---|---|---|---|---|---|
| Baseline lung function | 164 | 70 | 204 | ||||
| FEV1 % predicted | 94 ± 11 | 66 ± 11 | 62 ± 22 | <.0001‡ | |||
| FVC % predicted | 100 ± 12 | 81 ± 13 | 77 ± 20 | <.0001* | |||
| FEV1/FVC (%) | 80 ± 7 | 67 ± 10 | 65 ± 13 | <.0001‡ | |||
| Best lung function | 157 | 60 | 185 | ||||
| FEV1 % predicted | 102 ± 11 | 79 ± 12 | 77 ± 21 | <.0001‡ | |||
| FVC % predicted | 103 ± 13 | 91 ± 14 | 91 ± 18 | <.0001‡ | |||
| Maximal % change in FEV1 | 9 ± 7 | 20 ± 16 | 20 ± 24 | <.0001‡ | |||
| Methacholine PC20 (log mg/mL) | .24 ± .62 | 133 | −.11 ± .54 | 46 | −.06 ± .70 | 87 | .0002‡ |
| FeNO (ppb) | 42 ± 48 | 120 | 45 ± 39 | 55 | 40 ± 38 | 135 | .72 |
| Blood eosinophils (log) | −.72 ± .42 | 151 | −.63 ± .46 | 63 | −.75 ± .51 | 180 | .19 |
| Total serum IgE (log) | 2.0 ± .75 | 151 | 2.1 ± .63 | 63 | 2.0 ± .76 | 159 | .44 |
| ≥1 positive skin test (%) | 85% | 164 | 87% | 70 | 71% | 204 | .0007† |
*
Three-way comparison significant; all groups are different.
†
Three-way comparison, significant because of differences between severe vs mild and moderate.
‡
Three-way comparison, significant because of differences between mild vs moderate and severe.